Skip to main content
SpringerLink
Log in

Characterization and purification of a mycoplasma membrane-derived macrophage-activating factor

  • Original Articles
  • Macrophage Activation, Tumor Cytotoxicity, Mycoplasma Membrane, Purification
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

A highly hydrophobic component derived from the membrane ofMycoplasma capricolum has been characterized, purified and assessed for its ability to activate macrophages to tumor cytotoxicity. Initially, crude membranes were evaluated for their solubility in a wide range of solvents. Despite differential solubility in the various solvents, the mycoplasma membranes retained their ability to potentiate macrophage tumor cytotoxicity. Mycoplasma membranes were further characterized by appraising their macrophage-activating ability subsequent to various chemical treatments: cleavage of ester and thioester bonds, oxidation of vicinal hydroxyl groups, and exposure to a broad range of pH. Only strong alkaline treatment (pH>12) caused a reduction in mycoplasma membrane activity: all other chemical treatments were inconsequential. With potential therapeutic applications in mind, mycoplasma membranes were subjected to various physical treatments including heating, freezing/thawing, sonication, lyophilization and storage. The ability of the membranes to induce macrophage activation was stably maintained following all these treatments. Purification of membranes was initiated by a chloroform/methanol lipid extraction. Macrophage-activating ability was found predominantly in the interphase. Proteolytic cleavage with trypsin increased specific activity at least sixfold. Trypsinized fractions were solubilized in 2-chloroethanol and gel filtration was performed on a hydroxylated Sephadex LH-60 column. The active fraction from this column had a further tenfold increase in specific activity. Subsequent rounds of reverse-phase HPLC on this fraction yielded three to four peaks absorbing at 280 nm, of which only one had macrophage-activating ability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fidler IJ (1985) Macrophages and metastasis — a biological approach to cancer therapy: presidential address. Cancer Res 45: 4714–4726

    PubMed  Google Scholar 

  2. Fidler IJ, Raz A, Fogler WE, et al (1980) The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res 40: 4460–4466

    PubMed  Google Scholar 

  3. Schroit AJ, Fidler IJ (1982) Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 42: 161–167

    PubMed  Google Scholar 

  4. Key ME, Talmadge JE, Fogler WE, et al (1982) Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst 69: 1189–1198

    Google Scholar 

  5. Sanguedolce MV, Capo C, Bongrande P, Mege JL (1992) Zymosan-stimulated tumor necrosis factor-α production by human monocytes. J Immunol 148: 2229–2236

    PubMed  Google Scholar 

  6. Utsugi T, Nii A, Fan D, Pak CC, Denkins Y, Van Hoogevest P, Fidler IJ (1991) Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages. Cancer Immunol Immunother 33: 285–292

    PubMed  Google Scholar 

  7. Nii A, Utsugi T, Fan D, et al (1991) Optimization of the liposomes encapsulating a new lipopeptide CGP 31362 for efficient activation of tumoricidal properties in monocytes and macrophages. J Immunother 10: 236–246

    PubMed  Google Scholar 

  8. Lowenstein J, Rottem S, Gallily R (1983) Induction of macrophage-mediated cytolysis of neoplastic cells by mycoplasmas. Cell Immunol 77: 290–297

    PubMed  Google Scholar 

  9. Gallily R, Sher T, Ben Av P, Lowenstein J (1989) Tumor necrosis factor as a mediator ofMycoplasma orale tumor cell lysis by macrophages. Cell Immunol 121: 146–151

    PubMed  Google Scholar 

  10. Sher T, Yamin A, Matzliach M, Rottem S, Gallily R (1990) Partial biochemical characterization ofSpiroplasma membrane component inducing tumor necrosis factor alpha. Anticancer Drugs 1: 83–87

    PubMed  Google Scholar 

  11. Barile MT, Razin S, Tully JG, Whitcomb RF (1979) The mycoplasmas. Academic Press, London

    Google Scholar 

  12. Smith PF (1987) Antigenic character of membrane lipoglycans from Mollicutes: a review. Isr J Med Sci 23: 448–452

    PubMed  Google Scholar 

  13. Sher T, Rottem S, Gallily R (1990)Mycoplasma capricolum membranes induce tumor necrosis factor by a mechanism different from that of lipopolysaccharide. Cancer Immunol Immunother 31: 86–92

    PubMed  Google Scholar 

  14. Razin S, Rottem S (1970) Techniques for the manipulation of mycoplasma membranes. In: Maddy AH (ed) Biochemical analysis of membranes. Chapman & Hall, London

    Google Scholar 

  15. Minamide LS, Bamburg JR (1990) A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Anal Biochem 190: 66–70

    PubMed  Google Scholar 

  16. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911–917

    PubMed  Google Scholar 

  17. Hashimoto Y (1963) Action of enzymes on mucin. Ann NY Acad Sci 106: 233–246

    PubMed  Google Scholar 

  18. Sandermann H, Strominger JL (1972) Purification and properties of C55-isoprenoid alcohol phosphokinase fromStaphylococcus aureus. J Biol Chem 247: 5123–5131

    PubMed  Google Scholar 

  19. Zahler P, Weibel ER (1970) Reconstitution of membranes by recombining proteins and lipids derived from erythrocyte stroma. Biophys Biochim Acta 219: 320–338

    Google Scholar 

  20. Zahler PH, Wallach DFH (1967) Isolation of lipid-free plasma membrane proteins by gel filtration on Sephadex LH-20 using 2-chloroethanol-water as a solvent. Biophys Biochim Acta 135: 371–374

    Google Scholar 

  21. Tower D, Glaser L (1986) Protein fatty acid acylation: enzymatic synthesis of anN-myristoylglycyl peptide. Proc Natl Acad Sci USA 83: 2812–2816

    PubMed  Google Scholar 

  22. Gamberg GG, Hayry P, Andersson LC (1976) Characterization of surface glycoproteins of mouse lymphoid cells. J Cell Biol 68: 642–653

    PubMed  Google Scholar 

  23. Andreesen R, Scheibenbogen C, Brugger W, et al (1990) Adoptive transter of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 50: 7450–7456

    PubMed  Google Scholar 

  24. MacEwen EG, Kurzman ID, Rosenthal RC, et al (1989) Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81: 935–938

    PubMed  Google Scholar 

  25. Fidler IJ, Fogler WE, Brownbill AF, et al (1987) Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. J Immunol 138: 4509–4514

    PubMed  Google Scholar 

  26. Murray JL, Kleinerman ES, Cunningham JE, et al (1989) Phase I trial of liposomal muramyl tripeptide phospatidyl ethanolamine in cancer patients. J Clin Oncol 7: 1915–1925

    PubMed  Google Scholar 

  27. Bate CAW, Taverne J, Playfair JHL (1992) Detoxified exoantigens and phosphatidylinositol derivatives inhibit tumor necrosis factor induction by malarial exoantigens. Infect Immun 60: 1894–1901

    PubMed  Google Scholar 

  28. Ruuth E, Praz F (1989) Interactions between mycoplasmas and the immune system. Immunol Rev 112: 133–160

    PubMed  Google Scholar 

  29. Takema M, Oka S, Uno K, Nakamura S, Arita H, Tawara K, Inaba K, Muramatsu S (1991) Macrophage activating factor extracted from mycoplasmas. Cancer Immunol Immunother 33: 39–44

    PubMed  Google Scholar 

  30. Sugama K, Kuwono K, Furukawa M, et al (1990) Mycoplasmas induce transcription and production of tumor necrosis in a monocyte cell line, THP-1, by a protein kinase c-independent pathway. Infect Immun 58: 3564–3567

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Lautenberg Center for General and Tumor Immunology, The Hebrew University Medical School, P.O. Box 12272, 91120, Jerusalem, Israel

    Steve Caplan & Ruth Gallily

  2. The Department of Biochemistry, The Hebrew University Medical School, Jerusalem, Israel

    Yechezkel Barenholz

Authors
  1. Steve Caplan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruth Gallily
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yechezkel Barenholz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caplan, S., Gallily, R. & Barenholz, Y. Characterization and purification of a mycoplasma membrane-derived macrophage-activating factor. Cancer Immunol Immunother 39, 27–33 (1994). https://doi.org/10.1007/BF01517177

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01517177

Key words

Search

Navigation